Bugs, drugs and chemical genomics

Nature Chemical Biology

Volumn 8, Issue 1, 2012, Pages 46-56

  Roemer, Terry ^a   Davies, Julian ^b   Giaever, Guri ^c,d   Nislow, Corey ^c,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CAMPAFUNGIN; DENTIN MATRIX PROTEIN 1; DRETAMYCIN; ECC 1385; EXOSIN; FELLUTAMIDE C; FELLUTAMIDE D; FLUOROURACIL; MAC0003199; MAC0038968; MAC12343; PAMAFUNGIN; TARGOCIL; UNCLASSIFIED DRUG; YEFAFUNGIN;

CHEMICAL GENETICS; DRUG DEVELOPMENT; GENE; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

EID: 83655197492     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.744     Document Type: Review

References (97)

1. Boucher, H.W., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
2. Bancroft, E.A. Antimicrobials resistance: Its not just for hospitals. J. Am. Med. Assoc. 298, 1803-1804 (2007). (Pubitemid 47598451)
3. Klevens, R.M., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J. Am. Med. Assoc. 298, 1763-1771 (2007). (Pubitemid 47598444)
4. Fritsche, T.R., Sader, H.S. & Jones, R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn. Microbiol. Infect. Dis. 61, 86-95 (2008). (Pubitemid 351509753)
5. Hughes, D. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev. Genet. 4, 432-441 (2003). (Pubitemid 36648143)
6. Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007). (Pubitemid 46020284)
7. Davies, J. The garden of antimicrobial delights. F1000 Biol. Reprod. 12, 26 (2010).
8. Davies, J. How to discover new antibiotics: harvesting the parvome. Curr. Opin. Chem. Biol. 15, 5-10 (2011).
9. Baltz, R.H. Marcel Faber Roundtable: is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? J. Ind. Microbiol. Biotechnol. 33, 507-513 (2006). (Pubitemid 43876111)
10. Baltz, R.H. Renaissance in antibacterial discovery from actinomycetes. Curr. Opin. Pharmacol. 8, 557-563 (2008).
11. Roemer, T., et al. Confronting the challenges of natural product-based antifungal discovery. Chem. Biol. 18, 148-164 (2011).
12. Projan, S.J. Whither antibacterial drug discovery? Drug Discov. Today 13, 279-280 (2008).
13. Kalan, L. & Wright, G.D. Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Rev. Mol. Med. 13, e5 (2011).
14. Shuman, H.A. & Silhavy, T.J. The art and design of genetic screens: Escherichia coli. Nat. Rev. Genet. 4, 419-431 (2003). (Pubitemid 36648142)
15. Chin, C.S., et al. The origin of the Haitian cholera outbreak strain. N. Engl. J. Med. 364, 33-42 (2011).
16. Winzeler, E.A., et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285, 901-906 (1999). (Pubitemid 29381993)
17. Giaever, G., et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418, 387-391 (2002). (Pubitemid 34826834)
18. Peña-Castillo, L. & Hughes, T.R. Why are there still over 1000 uncharacterized yeast genes? Genetics 176, 7-14 (2007). (Pubitemid 350021004)
19. Hensel, M., et al. Simultaneous identification of bacterial virulence genes by negative selection. Science 269, 400-403 (1995).
20. Shoemaker, D.D., Lashkari, D.A., Morris, D., Mittmann, M. & Davis, R.W. Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat. Genet. 14, 450-456 (1996). (Pubitemid 26414589)
21. Pierce, S.E., Davis, R., Nislow, C. & Giaever, G. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat. Protoc. 2, 2958-2974 (2007).
22. Smith, A.M., et al. Quantitative phenotyping via deep barcode sequencing. Genome Res. 19, 1836-1842 (2009).
23. Giaever, G., et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21, 278-283 (1999). (Pubitemid 29124934)
24. Giaever, G., et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA 101, 793-798 (2004). (Pubitemid 38121037)
25. Lum, P.Y., et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116, 121-137 (2004). (Pubitemid 38156189)
26. St. Onge, R. al. Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions. Nat. Genet. 39, 199-206 (2007).
27. Hillenmeyer, M.E., et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320, 362-365 (2008). (Pubitemid 351555656)
28. Lain, S., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13, 454-463 (2008). (Pubitemid 351609441)
29. Hoon, S., St. Onge, R.P., Giaever, G. & Nislow, C. Yeast chemical genomics and drug discovery: an update. Trends Pharmacol. Sci. 29, 499-504 (2008).
30. Rodriguez-Suarez, R., et al. Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. Chem. Biol. 14, 1163-1175 (2007). (Pubitemid 47610739)
31. Oh, J., et al. Gene annotation and drug target discovery in Candida albicans with a tagged transposon mutant collection. PLoS Pathog. 6, e1001140 (2010).
32. Kohanski, M.A., Dwyer, D.J. & Collins, J.J. How antibiotics kill bacteria: from targets to networks. Nat. Rev. Microbiol. 8, 423-435 (2010).
33. Druker, B.J. & Lydon, N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3-7 (2000). (Pubitemid 30036380)
34. Lee, W., et al. Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS Genet. 1, e24 (2005).
35. Parsons, A.B., et al. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126, 611-625 (2006). (Pubitemid 44163601)
36. Birrell, G.W., et al. Transcriptional response of Saccharomyces cerevisiae to DNA-damaging agents does not identify the genes that protect against these agents. Proc. Natl. Acad. Sci. USA 99, 8778-8783 (2002). (Pubitemid 34700176)
37. Rine, J., Hansen, W., Hardeman, E. & Davis, R.W. Targeted selection of recombinant clones through gene dosage effects. Proc. Natl. Acad. Sci. USA 80, 6750-6754 (1983). (Pubitemid 14243225)
38. Hoon, S., et al. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat. Chem. Biol. 4, 498-506 (2008); erratum 4, 632 (2008).
39. Magtanong, L., et al. Dosage suppression genetic interaction networks enhance functional wiring diagrams of the cell. Nat. Biotechnol. 29, 505-511 (2011).
40. Wallace, I.M., et al. A method to rapidly identify bioactive small molecules in diverse model organisms. Chem. Biol. 18, 1273-1283 (2011).
41. Fillingham, J., et al. Two-color cell array screen reveals interdependent roles for histone chaperones and a chromatin boundary regulator in histone gene repression. Mol. Cell 35, 340-351 (2009).
42. Raisner, R.M. & Madhani, H.D. Genome-wide screen for negative regulators of sirtuin activity in Saccharomyces cerevisiae reveals 40 loci and links to metabolism. Genetics 179, 1933-1944 (2008).
43. Neklesa, T.K. & Davis, R.W.A. Genome-wide screen for regulators of TORC1 in response to amino acid starvation reveals a conserved Npr2/3 complex. PLoS Genet. 5, e1000515 (2009).
44. Hughes, T., Andrews, B. & Boone, C. Old drugs, new tricks: using genetically sensitized yeast to reveal drug targets. Cell 116, 5-7 (2004). (Pubitemid 38156180)
45. Kammler, S., Lykke-Andersen, S. & Jensen, T.H. The RNA exosome component hRrp6 is a target for 5-fluorouracil in human cells. Mol. Cancer Res. 6, 990-995 (2008).
46. Parsons, A.B., et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22, 62-69 (2004). (Pubitemid 38057958)
47. Ernst, R., Klemm, R., Schmitt, L. & Kuchler, K. Yeast ATP-binding cassette transporters: cellular cleaning pumps. Methods Enzymol. 400, 460-484 (2005). (Pubitemid 43052435)
48. Paumi, C.M., Chuk, M., Snider, J., Stagljar, I. & Michaelis, S. ABC transporters in Saccharomyces cerevisiae and their interactors: new technology advances the biology of the ABCC (MRP) subfamily. Microbiol. Mol. Biol. Rev. 73, 577-593 (2009).
49. Hall, M.D., Okabe, M., Shen, D.W., Liang, X.J. & Gottesman, M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol. 48, 495-535 (2008). (Pubitemid 351738162)
50. Wright, P.K. Targeting vesicle trafficking: an important approach to cancer chemotherapy. Recent Pat. Anticancer. Drug Discov. 3, 137-147 (2008).
51. Rajagopal, A. & Simon, S.M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 14, 3389-3399 (2003). (Pubitemid 37013135)
52. Xu, D., et al. Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog. 3, e92 (2007).
53. Lesage, G., et al. Analysis of beta-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 167, 35-49 (2004). (Pubitemid 38736368)
54. Roemer, T., et al. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol. Microbiol. 50, 167-181 (2003). (Pubitemid 37222795)
55. Hu, W., et al. Essential gene identification and drug target prioritization in Aspergillus fumigatus. PLoS Pathog. 3, e24 (2007).
56. Becker, J.M., et al. Pathway analysis of Candida albicans survival and virulence determinants in a murine infection model. Proc. Natl. Acad. Sci. USA 107, 22044-22049 (2010).
57. Xu, D., et al. Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans. J. Biol. Chem. 284, 19754-19764 (2009).
58. Jiang, B., et al. PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. Chem. Biol. 15, 363-374 (2008). (Pubitemid 351508424)
59. Herath, K., et al. Isolation, structure and biological activity of phomafungin, a cyclic lipodepsipeptide from a widespread tropical Phoma sp. Bioorg. Med. Chem. 17, 1361-1369 (2009).
60. Ondeyka, J., et al. Isolation, structure elucidation, and biological activity of virgineone from Lachnum Wirgineum using the genome-wide Candida albicans fitness test. J. Nat. Prod. 72, 136-141 (2009).
61. Bills, G.F., et al. Discovery of the parnafungins, antifungal metabolites that inhibit mRNA polyadenylation, from the Fusarium larvarum complex and other Hypocrealean fungi. Mycologia 101, 449-472 (2009).
62. Barker, C.A., Farha, M.A. & Brown, E.D. Chemical genomic approaches to study model microbes. Chem. Biol. 17, 624-632 (2010).
63. Baba, T., et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008 (2006).
64. Nichols, R.J., et al. Phenotypic landscape of a bacterial cell. Cell 144, 143-156 (2011).
65. Tamae, C., et al. Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J. Bacteriol. 190, 5981-5988 (2008).
66. Girgis, H.S., Hottes, A.K. & Tavazoie, S. Genetic architecture of intrinsic antibiotic susceptibility. PLoS ONE 4, e5629 (2009).
67. Liu, A., et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob. Agents Chemother. 54, 1393-1403 (2010).
68. Flores, A.R., Parsons, L.M. & Paelka, M.S. Jr. Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to βlactam Antibiotics. J. Bacteriol. 187, 1892-1900 (2005). (Pubitemid 40316217)
69. Gomez, M.J. & Neyfakh, A.A. Genes involved in intrinsic antibiotic resistance of Acinetobacter baylyi. Antimicrob. Agents Chemother. 50, 3562-3567 (2006). (Pubitemid 44684866)
70. Fajardo, A., et al. The neglected intrinsic resistome of bacterial pathogens. PLoS One 3, e1619 (2008).
71. Pathania, R., et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat. Chem. Biol. 5, 849-856 (2009).
72. Farha, M.A. & Brown, E.D. Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity. Chem. Biol. 17, 852-862 (2010).
73. Donald, R.G.K., et al. A novel Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. Chem. Biol. 16, 826-836 (2009).
74. Xu, H.H., et al. Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials. Antimicrob. Agents Chemother. 54, 3659-3670 (2010).
75. Huber, J., et al. Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem. Biol. 16, 837-848 (2009).
76. Wang, H., Claveau, D., Vaillancourt, J.P., Roemer, T. & Meredith, T.C. High frequency transposition in Staphylococcus aureus via bacteriophage delivery for determining antibacterial mode of action. Nat. Chem. Biol. 7, 720-729 (2011).
77. Lee, S.H., et al. Antagonism of chemical genetic interaction networks re-sensitize methicillin-resistant Staphylococcus aureus to βlactam antibiotics. Chem. Biol. 18, 1379-1389 (2011).
78. Swoboda, J.G., et al. Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus. ACS Chem. Biol. 4, 875-883 (2009).
79. Weidenmaier, C. & Peschel, A. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat. Rev. Microbiol. 6, 276-287 (2008). (Pubitemid 351404772)
80. Swoboda, J.G., et al. Wall teichoic acid function, biosynthesis, and inhibition. ChemBioChem 11, 35-45 (2010).
81. DElia, M.A., Pereira, M.P. & Brown, E.D. Are essential genes really essential? Trends Microbiol. 17, 433-438 (2009).
82. DElia, M.A., et al. Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis. Chem. Biol. 16, 548-556 (2009).
83. Suzuki, T., Swoboda, J.G., Campbell, J., Walker, S. & Gilmore, M.S. In vitro antimicrobial activity of wall teichoic acid biosynthesis inhibitors against Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55, 767-774 (2011).
84. Lee, K., Campbell, J., Swoboda, J.G., Cuny, G.D. & Walker, S. Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus. Bioorg. Med. Chem. Lett. 20, 1767-1770 (2010).
85. Weidenmaier, C., et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat. Med. 10, 243-245 (2004). (Pubitemid 38667612)
86. Weidenmaier, C., et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J. Infect. Dis. 191, 1771-1777 (2005). (Pubitemid 40656767)
87. Weidenmaier, C., McLoughlin, R.M. & Lee, J.C. The zwitterionic cell wall teichoic acid of Staphylococcus aureus provokes skin abscesses in mice by a novel CD4+ T-cell-dependent mechanism. PLoS ONE 5, e13227 (2010).
88. Campbell, J., et al. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. ACS Chem. Biol. 6, 106-116 (2011).
89. Oh, J., et al. A universal TagModule collection for parallel genetic analysis of microorganisms. Nucleic Acids Res. 38, e146 (2010).
90. Opijnen, van T., Bodi, K.L. & Camilli, A. Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. Nat. Methods 6, 767-772 (2009).
91. Langridge, G.C., et al. Simultaneous assay of every Salmonella typhi gene using one million transposon mutants. Genome Res. 19, 2308-2316 (2009).
92. Serizawa, M., et al. Genome-wide screening for novel genetic variations associated with ciprofloxacin resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 54, 2787-2792 (2010).
93. Moffatt, J.H., et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54, 4971-4977 (2010).
94. Ioerger, T.R., et al. Genome analysis of multi-and extensively-drug- resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS ONE 4, e7778 (2009).
95. Bentley, S.D., et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature 417, 141-147 (2002). (Pubitemid 34506788)
96. Arnoldo, A., et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet. 4, e1000005 (2008); erratum 4, doi:10.1371/annotation/76d35829-07a2-479f-bbc1- cce6755b6d8c.
97. Smith, A.M., et al. Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples. Nucleic Acids Res. 38, e142 (2010).